NeuroBo Pharmaceuticals (NRBO) has announced the signing of an exclusive license agreement granting MThera Pharma Co. the rights to NB-01, intended for the treatment of painful diabetic neuropathy. This agreement authorizes MThera to conduct research and clinical trials, including a potential Phase 3 clinical trial in both the United States and South Korea, paving the way for the future commercialization of NB-01.
"Based on the positive Phase 2 efficacy results for NB-01 in treating diabetic neuropathy, we plan to develop it as a potential treatment for peripheral diabetes," stated Mi Won Sohn, CEO of MThera.
